fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

European Commission approves Veklury a treatment for COVID-19 infection.- Gilead Sciences

Written by | 5 Jul 2020

Gilead Sciences, Inc.announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional… read more.

Kevzara phase III U.S. trial in COVID-19 patients does not meet endpoints. Sanofi + Regeneron

Written by | 3 Jul 2020

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the . Phase III trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary… read more.

Preliminary data shows that BNT 162b1 is safe and immunologically active in COVID-19.- Pfizer and BioNTech

Written by | 2 Jul 2020

Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT 162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2. The BNT… read more.

Two phase I studies of INO 4800 report safety in COVID-19.- Inovio

Written by | 1 Jul 2020

Inovio has announced positive interim clinical data of INO 4800 vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase I clinical trial cohorts. In addition, INO… read more.

UK approves phase II/III study evaluating Yeliva in patients hospitalized with severe SARS-CoV-2 infection.- RedHill Biopharma

Written by | 30 Jun 2020

RedHill Biopharma Ltd. announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Company’s Clinical Trial Authorization application to commence a Phase II/III study… read more.

CHMP recommends approval of Veklury for COVID-19 (novel coronavirus).- Gilead Sciences

Written by | 28 Jun 2020

The EU Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Veklury (remdesivir),… read more.

Fulcrum THerapeutics initiates phase III trial of losmapimod to treat COVID-19.

Written by | 25 Jun 2020

Fulcrum Therapeutics, Inc. announced that it received early notification from the FDA that the company may proceed with initiating a Phase III, randomized, double-blind, placebo-controlled trial of losmapimod… read more.

FDA grants emergency use authorisation for GenePro SARS-CoV-2 Test as diagnostic for COVID-19.- Gencurix

Written by | 25 Jun 2020

Gencurix has received FDA Emergency Use Authorization for its GenePro SARS-CoV-2 Test. It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro… read more.

Indian government approves FabiFlu for mild to moderate COVID-19 patients.- Glenmark Pharma

Written by | 23 Jun 2020

Glenmark Pharmaceuticals announced the launch of antiviral drug FabiFlu (favipiravir) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s… read more.

Ridgeback Biotherapeutics announces the launch of two phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19.Merck Inc.

Written by | 21 Jun 2020

Ridgeback Biotherapeutics announces the launch of two Phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19. Phase I trials recently… read more.

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19.- Generic

Written by | 18 Jun 2020

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including… read more.

Is indomethacin a better choice than ibuprofen in covid-19?

Written by | 17 Jun 2020

Interview and article by Christine Clark. Compared with ibuprofen, indomethacin has additional beneficial actions, argues Dr Rajan Ravichandran Commenting on the LIBERATE* study (NCT04334629) that is now in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.